GTBP Stock Overview
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform.
+ 2 more risks
GT Biopharma Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$2.60|
|52 Week High||US$10.91|
|52 Week Low||US$1.51|
|1 Month Change||-10.35%|
|3 Month Change||34.72%|
|1 Year Change||-75.95%|
|3 Year Change||-30.48%|
|5 Year Change||-99.45%|
|Change since IPO||-100.00%|
Recent News & Updates
GT Biopharma GAAP EPS of -$0.10 beats by $0.07
GT Biopharma press release (NASDAQ:GTBP): Q2 GAAP EPS of -$0.10 beats by $0.07. The Company had total cash, cash equivalents and short-term investments of $23.7 million as of June 30, 2022, compared to $32.0 million as of December 31, 2021. This is expected to provide ample runway to fund operations into 2023.
Here's Why We're Watching GT Biopharma's (NASDAQ:GTBP) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
|GTBP||US Biotechs||US Market|
Return vs Industry: GTBP underperformed the US Biotechs industry which returned -22.1% over the past year.
Return vs Market: GTBP underperformed the US Market which returned -11.6% over the past year.
|GTBP Average Weekly Movement||12.5%|
|Biotechs Industry Average Movement||12.5%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: GTBP is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: GTBP's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors.
GT Biopharma Fundamentals Summary
|GTBP fundamental statistics|
Is GTBP overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|GTBP income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.11|
|Net Profit Margin||0.00%|
How did GTBP perform over the long term?See historical performance and comparison
Is GTBP undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for GTBP?
Other financial metrics that can be useful for relative valuation.
|What is GTBP's n/a Ratio?|
Price to Book Ratio vs Peers
How does GTBP's PB Ratio compare to its peers?
|GTBP PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
JSPR Jasper Therapeutics
SLDB Solid Biosciences
PYXS Pyxis Oncology
GTH Genetron Holdings
GTBP GT Biopharma
Price-To-Book vs Peers: GTBP is expensive based on its Price-To-Book Ratio (4.5x) compared to the peer average (0.7x).
Price to Earnings Ratio vs Industry
How does GTBP's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Book vs Industry: GTBP is expensive based on its Price-To-Book Ratio (4.5x) compared to the US Biotechs industry average (1.8x)
Price to Book Ratio vs Fair Ratio
What is GTBP's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||4.5x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate GTBP's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of GTBP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate GTBP's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate GTBP's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
How is GT Biopharma forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GTBP is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: GTBP is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: GTBP is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: GTBP is forecast to have no revenue next year.
High Growth Revenue: GTBP is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if GTBP's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has GT Biopharma performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GTBP is currently unprofitable.
Growing Profit Margin: GTBP is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: GTBP is unprofitable, but has reduced losses over the past 5 years at a rate of 22.1% per year.
Accelerating Growth: Unable to compare GTBP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GTBP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.5%).
Return on Equity
High ROE: GTBP has a negative Return on Equity (-189.87%), as it is currently unprofitable.
Discover strong past performing companies
How is GT Biopharma's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: GTBP's short term assets ($27.2M) exceed its short term liabilities ($9.5M).
Long Term Liabilities: GTBP's short term assets ($27.2M) exceed its long term liabilities ($147.0K).
Debt to Equity History and Analysis
Debt Level: GTBP is debt free.
Reducing Debt: GTBP currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GTBP has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: GTBP has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 24.4% each year.
Discover healthy companies
What is GT Biopharma current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate GTBP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate GTBP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GTBP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GTBP's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as GTBP has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Michael Breen (59 yo)
Mr. Michael Martin Breen serves as Interim Chief Executive Officer at GT Biopharma, Inc. since March 02, 2022. Mr. Breen serves as Executive Chairman at GT Biopharma, Inc. since November 08, 2021 and serve...
CEO Compensation Analysis
Compensation vs Market: Michael's total compensation ($USD2.83M) is above average for companies of similar size in the US market ($USD765.66K).
Compensation vs Earnings: Insufficient data to compare Michael's compensation with company performance.
Experienced Management: GTBP's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.
Experienced Board: GTBP's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 44.4%.
GT Biopharma, Inc.'s employee growth, exchange listings and data sources
- Name: GT Biopharma, Inc.
- Ticker: GTBP
- Exchange: NasdaqCM
- Founded: 1965
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$79.302m
- Shares outstanding: 30.50m
- Website: https://www.gtbiopharma.com
Number of Employees
- GT Biopharma, Inc.
- 8000 Marina Boulevard
- Suite 100
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/11 00:00|
|End of Day Share Price||2022/08/11 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.